A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

Published:2006-05-08 Issue:20 Volume:103 Page:7795-7800
ISSN:0027-8424
Container-title:Proceedings of the National Academy of Sciences
language:en
Short-container-title:Proceedings of the National Academy of Sciences

Author:

Xia W.,Bacus S.,Hegde P.,Husain I.,Strum J.,Liu L.,Paulazzo G.,Lyass L.,Trusk P.,Hill J.,Harris J.,Spector N. L.

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

Reference41 articles.

1. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

2. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies

3. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

4. Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and c-erbB-2

Cited by 317 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BioFusionNet: Deep Learning-Based Survival Risk Stratification in ER+ Breast Cancer Through Multifeature and Multimodal Data Fusion;IEEE Journal of Biomedical and Health Informatics;2024-09

2. Genomic profiling and comparative analysis of male versus female metastatic breast cancer across subtypes;Breast Cancer Research;2024-07-24

3. Decrease in GPSM2 mediated by the natural product luteolin contributes to colon adenocarcinoma treatment and increases the sensitivity to fluorouracil;Biomedicine & Pharmacotherapy;2024-07

4. HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review;Medicine;2024-06-14

5. Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer;Current Problems in Cancer;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3